LeonaBio, Inc. recently showcased promising nonclinical data on lasofoxifene at the AACR26, presented by researchers from Virginia Commonwealth University. The findings highlight lasofoxifene’s dual role as a selective estrogen receptor modulator (SERM) that not only suppresses ER-driven tumor growth in metastatic breast cancer but also preserves bone integrity, particularly in models of ESR1-mutant disease. This unique context-dependent activity positions lasofoxifene as a potentially transformative therapeutic candidate for patients facing metastatic breast cancer with limited treatment options.

The significance of these findings lies in lasofoxifene’s ability to address two critical challenges: reducing metastatic tumor burden in bone while maintaining a favorable bone microenvironment. In previous Phase 2 studies, lasofoxifene demonstrated improved outcomes compared to traditional therapies, including longer median progression-free survival (5.6 months vs. 3.7 months) and higher objective response rates (13.3% vs. 2.9%). These results underscore the potential of lasofoxifene to not only enhance anti-tumor efficacy but also provide quality-of-life benefits for patients, which is crucial in the context of metastatic disease.

The ongoing ELAINE-3 Phase 3 trial aims to establish lasofoxifene as a new standard of care for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. This trial’s outcomes could significantly shift current research paradigms by validating lasofoxifene’s efficacy in a genetically defined patient population, potentially accelerating drug development timelines and offering a novel therapeutic option where few exist. As research progresses, lasofoxifene may redefine treatment strategies for managing metastatic breast cancer, particularly in patients with resistance to existing therapies.

Source: globenewswire.com